{"name":"Santen SAS","slug":"santen-sas","ticker":"","exchange":"","domain":"","description":"Santen SAS is a leading ophthalmic pharmaceutical company dedicated to improving the lives of patients with eye diseases and disorders. The company has a strong focus on research and development, with a pipeline of innovative treatments in various stages of clinical development.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"NOVA22007","genericName":"NOVA22007","slug":"nova22007","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"Masked Ikervis","genericName":"Masked Ikervis","slug":"masked-ikervis","indication":"Dry eye disease with significant inflammatory component","status":"phase_3"},{"name":"NOVA22007 (Ciclosporin 0.1%)","genericName":"NOVA22007 (Ciclosporin 0.1%)","slug":"nova22007-ciclosporin-0-1","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"Open-label Ikervis","genericName":"Open-label Ikervis","slug":"open-label-ikervis","indication":"Severe keratoconjunctivitis sicca (dry eye disease) in adults","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"DE-130A","genericName":"DE-130A","slug":"de-130a","indication":"Glaucoma or ocular hypertension (Phase 3 indication)","status":"phase_3"},{"name":"DE-130A/DE-130A","genericName":"DE-130A/DE-130A","slug":"de-130a-de-130a","indication":"Glaucoma","status":"phase_3"},{"name":"Xalatan®/DE-130A","genericName":"Xalatan®/DE-130A","slug":"xalatan-de-130a","indication":"Glaucoma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Cyclosporine NOVA22007 0.05%","genericName":"Cyclosporine NOVA22007 0.05%","slug":"cyclosporine-nova22007-0-05","indication":"Treatment of uveitis","status":"phase_2"},{"name":"NOVA63035 \"Corticosteroid\"","genericName":"NOVA63035 \"Corticosteroid\"","slug":"nova63035-corticosteroid","indication":"Inflammatory ocular conditions (likely, based on Santen's focus)","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"NOVA22007 ''Ciclosporin''","genericName":"NOVA22007 ''Ciclosporin''","slug":"nova22007-ciclosporin","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"}]}],"pipeline":[{"name":"NOVA22007","genericName":"NOVA22007","slug":"nova22007","phase":"phase_3","mechanism":"NOVA22007 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces neurogenic inflammation and pain signaling in the eye.","indications":["Dry eye disease (keratoconjunctivitis sicca)","Ocular pain and inflammation"],"catalyst":""},{"name":"Cyclosporine NOVA22007 0.05%","genericName":"Cyclosporine NOVA22007 0.05%","slug":"cyclosporine-nova22007-0-05","phase":"phase_2","mechanism":"Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation.","indications":["Treatment of uveitis"],"catalyst":""},{"name":"DE-130A","genericName":"DE-130A","slug":"de-130a","phase":"phase_3","mechanism":"DE-130A is a small-molecule inhibitor designed to modulate intraocular pressure and inflammation in the eye.","indications":["Glaucoma or ocular hypertension (Phase 3 indication)"],"catalyst":""},{"name":"DE-130A/DE-130A","genericName":"DE-130A/DE-130A","slug":"de-130a-de-130a","phase":"phase_3","mechanism":"DE-130A is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma and ocular hypertension.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Masked Ikervis","genericName":"Masked Ikervis","slug":"masked-ikervis","phase":"phase_3","mechanism":"Ikervis is a cyclosporine A ophthalmic emulsion that suppresses local immune-mediated inflammation in the ocular surface.","indications":["Dry eye disease with significant inflammatory component"],"catalyst":""},{"name":"NOVA22007 ''Ciclosporin''","genericName":"NOVA22007 ''Ciclosporin''","slug":"nova22007-ciclosporin","phase":"phase_3","mechanism":"Ciclosporin suppresses T-cell activation and proliferation by inhibiting calcineurin, thereby reducing inflammatory immune responses.","indications":["Dry eye disease (keratoconjunctivitis sicca)","Uveitis","Other immune-mediated ocular inflammatory conditions"],"catalyst":""},{"name":"NOVA22007 (Ciclosporin 0.1%)","genericName":"NOVA22007 (Ciclosporin 0.1%)","slug":"nova22007-ciclosporin-0-1","phase":"phase_3","mechanism":"Ciclosporin is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.","indications":["Dry eye disease (keratoconjunctivitis sicca)"],"catalyst":""},{"name":"NOVA63035 \"Corticosteroid\"","genericName":"NOVA63035 \"Corticosteroid\"","slug":"nova63035-corticosteroid","phase":"marketed","mechanism":"NOVA63035 is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors.","indications":["Inflammatory ocular conditions (likely, based on Santen's focus)"],"catalyst":""},{"name":"Open-label Ikervis","genericName":"Open-label Ikervis","slug":"open-label-ikervis","phase":"phase_3","mechanism":"Ikervis is a lipid emulsion eye drop that reduces inflammation and promotes tear production in dry eye disease by delivering cyclosporine to the ocular surface.","indications":["Severe keratoconjunctivitis sicca (dry eye disease) in adults"],"catalyst":""},{"name":"Xalatan®/DE-130A","genericName":"Xalatan®/DE-130A","slug":"xalatan-de-130a","phase":"phase_3","mechanism":"Xalatan is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPcnRRb0hYVmtZcDY0WE5FRXNPajRFNE9lOGhVcXF4XzFYY18yVEFUUVJ4U2VzU21xTGNINlJIQkowaHU3aGtmS1ZRcnA0VldoelZZVFpzaER0QnY5MWVGMTZmT09kcFhoY1RBV0MzWTQ3dFJmZS1xM0pEY0Q4bG5tNnFKUlRqcGNMR21wSjY0Qnd6bTVZWFZheFVKdTMxNzdqWWdfMUtXdjl6dy1nS2gwYzZnWDJRZ3BlX1RXYmpR0gFaQVVfeXFMUDE4cjNDc1lHbUZLRUtWYm55Si1zNDNXa0ZadTgwZGJBdlFoSkg2MTl5S1RCUFhibFdXc0RsdEdHMHgyenZUU3E0VWFwYkFpZjFTUGFCQWxIVGhn?oc=5","date":"2025-01-28","type":"pipeline","source":"MLex","summary":"Merck properly denied extra period of exclusivity for cladribine, UK panel says - MLex","headline":"Merck properly denied extra period of exclusivity for cladribine, UK panel says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQeHhISHVyb2Z5d2h0aGoyZW4takJhLTlQaDlYbFFlaTRvMnBrN3h6cEttemhWelM0SzRkRFlzVlkzTkdET1dqb2xZcVdjZ0pKWGZIVnd0QnBDRHJjN0J3WXZmaWRpU0g4VndCYk9zSE94dF80VWNWX01MYXpJci02SFozdHlOdlR2TkM0ckNpdjBzVHE5U2hVUzc0U0dMODBXZkNYY08xOFh1OE53eWRRYi03cUIwQlh3d0JvTU41djhNMm9Mc3hBelZldmRETjlQd3ptNmlkY2RuQm9zR1F4WlMzeVQyUnhxeDdBSUNSbjRJX1NLVjI0ZEs0bmY3dWh4dDd1TFZKbjlpNTlIeXdqdm9PWG1mS3hEMTNTTmRjZw?oc=5","date":"2025-01-20","type":"trial","source":"GlobeNewswire","summary":"Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire","headline":"Advancements in Ocular Hypertension Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxOcTFsdWh2ejBfaDNLQ1RrdmxPUTFpVkxaUXhLRHB0SDJBc2R5ZkUyaTNhMWp3OGJJZVB5b3pheUhVNTFqVVl5TVVlZml5Rk5qSHBMelVxV1BORjVySEJrYkxPRVk4SU1QaC1sNno2M2JoU0R5UXFyTDFCcWtTa0F5RF90aXZqeDNOT2dudWVGbkoweEdaZnpsYmRNeGl1aVJSR1ZHczJ4TlphWkRlcU1DbEU0V1RjWHBDQmVoaF9zRzdSZXc4S0RWQXozRkVmNEY0U2Q0eUIybWs4TmZrMnAxbFdocDAyNkZYRjQxejN0SEVqVGlZUXVVbFlLUHZoSG9OTUE?oc=5","date":"2023-05-18","type":"trial","source":"PR Newswire","summary":"Glaucoma Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Developing Drugs for the Market Entry - PR Newswire","headline":"Glaucoma Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Developing Drugs for the Market Entry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFA4T0Q2MUxnV1pjUi1XSTdaOTQ4SW9CRGVoNTd4TkZucTR5YTNuUmtBeVkzTTdJOC1zY21tNVNpalJkeDhSS0tMTEJjWkRGWHpaakdiclhzbTV1WmVfYUcw?oc=5","date":"2022-12-23","type":"trial","source":"Nature","summary":"Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials - Nature","headline":"Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of random","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTFBlektGb0JxUXRERHkzQzc1d3dKR1ZRbnR2LTNKV2x4TUpKSjAyWHc1dzROQm04UTV1bjdLUU9JRTFBelZyLTEwR3Y2Vl9xNFp4WTdBMExRVVo3amM?oc=5","date":"2017-03-01","type":"trial","source":"sas.com","summary":"Improving eye health via clearer data analysis - sas.com","headline":"Improving eye health via clearer data analysis","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_3":8,"phase_2":1,"marketed":1},"enrichmentLevel":2,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}